抗体工程市场规模、份额及成长分析（按产品、製程、类型、最终用途和地区划分）－产业预测（2026-2033）

预计到 2024 年，抗体工程市场规模将达到 209.1 亿美元，到 2025 年将达到 236.1 亿美元，到 2033 年将达到 623.1 亿美元，在预测期（2026-2033 年）内，复合年增长率为 12.9%。

抗体工程市场预计将迎来显着成长，这主要得益于标靶治疗、诊断和疫苗领域对抗体需求的激增。生物技术的进步以及对分子层面疾病机制的深入理解，凸显了特异性抗体的重要性，这些抗体对于研究疾病路径和推进个人化医疗至关重要。慢性病和感染疾病发病率的不断上升进一步刺激了市场需求，而抗体在治疗癌症、自体免疫疾病和其他疾病方面已展现出疗效。精准医疗计划也进一步提升了市场潜力。此外，重组DNA技术和高通量筛检等技术创新正在简化生产流程，提高扩充性和效率。总而言之，儘管仍存在一些挑战，但医疗保健和製药领域蕴藏着巨大的创新机会。

抗体工程市场驱动因素

慢性病发病率的上升，以及人们对标靶治疗日益增长的需求，正显着推动抗体疗法的需求成长。抗体具有独特的特异性和疗效，可用于治疗多种疾病，包括癌症、自体免疫疾病和感染疾病。单株抗体（mAb）的进步和应用已彻底改变了治疗方法，催生了许多以抗体技术为核心、疗效显着的药物。随着医疗系统寻求更有效的治疗方案来应对复杂多样的医疗挑战，精准医疗的兴起正在推动抗体工程市场的发展。

限制抗体生产市场的因素

抗体研发和生产的复杂流程、巨额研发投入以及对大规模生产能力的需求，导致成本高昂，为抗体生产市场带来了巨大挑战。高昂的成本阻碍了中小企业进入市场，限制了它们有效竞争的能力。此外，抗体生产的成本壁垒也限制了抗体治疗方法的可近性和普及性。这种经济壁垒最终会阻碍整个市场的成长，因为定价结构可能会使许多医疗服务提供者和患者无法受益于这些创新治疗方法。

抗体生产市场趋势

在对个人化医疗解决方案日益重视的推动下，抗体工程市场正经历着向个人化医疗的重大转变。基因组学和蛋白​​质组学技术的不断进步提高了识别特定疾病标记的能力，从而促进了客製化标靶疗法的开发。这一趋势不仅提高了治疗效果，还最大限度地减少了副作用，满足了患者对更个人化治疗方案的需求。因此，针对个别患者特征客製化抗体的开发和生产正成为重点，随着医疗保健越来越重视精准性和个人化，预计该市场将持续成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析
• 案例研究分析
• 专利分析

全球抗体生产市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 装置
  • 生物反应器
  • 多用途生物反应器
  • 免洗生物反应器
  • 其他的
• 层析法系统
• 过滤系统
• 消耗品
  • 媒体
  • 缓衝液和试剂
  • 层析法树脂和色谱管柱
  • 过滤耗材及配件
  • 其他的
• 软体

全球抗体生产市场规模（按製程和复合年增长率划分）（2026-2033 年）

• 上游工程
• 下游工艺

全球抗体生产市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 多株抗体
• 单株抗体

全球抗体生产市场规模（按最终用途和复合年增长率划分）（2026-2033 年）

• 製药和生物技术公司
• 研究所
• CROS 和 CDMOS

全球抗体生产市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Roche（Switzerland）
• Genmab（Denmark）
• Amgen（US）
• Biogen（US）
• Johnson & Johnson（US）
• AbbVie（US）
• AstraZeneca（UK）
• Novartis（Switzerland）
• Pfizer（US）
• Sanofi（France）
• Merck & Co.（US）
• Gilead Sciences（US）
• Celgene（US）
• BioMarin Pharmaceutical（US）
• Shire（Ireland）
• Alexion Pharmaceuticals（US）
• Teva Pharmaceuticals（Israel）
• Allergan（US）
• Bristol Myers Squibb（US）
• Novo Nordisk（Denmark）

结论与建议

Antibody Production Market size was valued at USD 20.91 Billion in 2024 and is poised to grow from USD 23.61 Billion in 2025 to USD 62.31 Billion by 2033, growing at a CAGR of 12.9% during the forecast period (2026-2033).

The antibody production market is poised for significant growth, driven by the surging demand for antibodies essential in targeted therapies, diagnostics, and vaccines. Advances in biotechnology and a deeper understanding of molecular disease mechanisms highlight the necessity for specific antibodies, crucial for studying disease pathways and facilitating personalized medicine. The increasing incidence of chronic and infectious diseases amplifies this demand, with antibodies demonstrating efficacy in treating conditions like cancer and autoimmune disorders. The drive towards precision medicine further enhances market potential. Moreover, technological innovations, including recombinant DNA technology and high-throughput screening, are streamlining production processes, offering scalability and efficiency. Overall, while challenges persist, the market presents ample opportunities for innovation within the healthcare and pharmaceutical sectors.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antibody Production market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antibody Production Market Segments Analysis

Global Antibody Production Market is segmented by product, process, type, end use and region. Based on product, the market is segmented into instruments, chromatography systems, filtration systems, consumables and software. Based on process, the market is segmented into upstream processing and downstream processing. Based on type, the market is segmented into polyclonal antibody and monoclonal antibody. Based on end use, the market is segmented into pharmaceutical and biotechnology companies, research laboratories and cros and cdmos. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Antibody Production Market

The rising incidence of chronic illnesses, coupled with a growing preference for targeted treatment options, is significantly driving the demand for antibody-based therapeutics. Antibodies possess unique specificity and effectiveness for addressing a range of health conditions, such as cancer, autoimmune diseases, and infectious disorders. The advancement and application of monoclonal antibodies (mAbs) have transformed therapeutic approaches, leading to the introduction of several widely successful drugs that are centered around antibody technologies. This shift towards precision medicine is propelling the antibody production market, as healthcare systems seek more effective treatment solutions for complex and diverse medical challenges.

Restraints in the Antibody Production Market

The intricate processes involved in antibody development and production, alongside the substantial research and development investments and the necessity for large-scale manufacturing capabilities, lead to elevated costs that pose a considerable challenge within the antibody production market. These high expenses often hinder the participation of small and medium-sized enterprises, limiting their ability to compete effectively. Furthermore, the cost-prohibitive nature of antibody production restricts the affordability and accessibility of antibody-based therapies. This financial barrier consequently impedes overall market growth, as the pricing structures may prevent a wider range of healthcare providers and patients from benefiting from these innovative treatments.

Market Trends of the Antibody Production Market

The antibody production market is experiencing a significant shift towards personalized medicine, driven by an increasing emphasis on tailored healthcare solutions. As advancements in genomic and proteomic technologies continue to evolve, there is greater capability to identify specific disease markers, facilitating the creation of custom-targeted therapies. This trend not only enhances treatment efficacy but also minimizes side effects, resonating with patients' demand for more individualized care options. Consequently, the development and production of antibodies that can specifically address unique patient profiles is becoming a pivotal focus, positioning the market for continued growth as healthcare increasingly prioritizes precision and personalization.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Case Study Analysis
• Patent Analysis

Global Antibody Production Market Size by Product & CAGR (2026-2033)

• Market Overview
• Instruments
  • Bioreactors
  • Multi-Use Bioreactors
  • Single-Use Bioreactors
  • Others
• Chromatography Systems
• Filtration Systems
• Consumables
  • Media
  • Buffers And Reagents
  • Chromatography Resins And Columns
  • Filtration Consumables And Accessories
  • Others
• Software

Global Antibody Production Market Size by Process & CAGR (2026-2033)

• Market Overview
• Upstream Processing
• Downstream Processing

Global Antibody Production Market Size by Type & CAGR (2026-2033)

• Market Overview
• Polyclonal Antibody
• Monoclonal Antibody

Global Antibody Production Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Pharmaceutical And Biotechnology Companies
• Research Laboratories
• CROS and CDMOS

Global Antibody Production Market Size & CAGR (2026-2033)

• North America (Product, Process, Type, End Use)
  • USA
  • Canada
• Europe (Product, Process, Type, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Process, Type, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Process, Type, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Process, Type, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alexion Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations